Promore Pharma’s rights issue completed
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE CONTRAVENING TO ANY APPLICABLE RULES.Promore Pharma AB (publ) (”Promore Pharma” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders has been completed (the “Rights Issue”). The Rights Issue was subscribed to 80 percent, providing Promore Pharma with gross proceeds of